tafluposide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9877073 |
| CHEMBL ID | 3989413 |
| SCHEMBL ID | 26426 |
| MeSH ID | M0577431 |
| Synonym |
|---|
| tafluposide [inn] |
| unii-qn043x3zdw |
| f 11782 |
| tafluposide |
| 4-((5r,5ar,8ar,9s)-9-((4,6-o-((1r)-ethylidene)-2,3-biso-((pentafluorophenoxy)acetyl)-beta-d-glucopyranosyl)oxy)-6-oxo-5,5a,6,8,8a,9-hexahydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-5-yl)-2,6-dimethoxyphenyle dihydrogen phosphate |
| f-11782 |
| 179067-42-6 |
| qn043x3zdw , |
| SCHEMBL26426 |
| 4-((5r,5ar,8ar,9s)-9-((4,6-o-((1r)-ethylidene)-2,3-bis-o-((pentafluorophenoxy)acetyl)-.beta.-d-glucopyranosyl)oxy)-6-oxo-5,5a,6,8,8a,9-hexahydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-5-yl)-2,6-dimethoxyphenyl dihydrogen phosphate |
| DTXSID50170767 |
| [(2r,4ar,6r,7r,8s,8ar)-6-[[(5s,5ar,8ar,9r)-9-(3,5-dimethoxy-4-phosphonooxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-5-yl]oxy]-2-methyl-7-[2-(2,3,4,5,6-pentafluorophenoxy)acetyl]oxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]d |
| CHEMBL3989413 |
| Q27287346 |
| AKOS040749605 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "F 11782 in combination with cisplatin, mitomycin C, etoposide or doxorubicin showed synergistic cytotoxicity against both cell lines." | ( Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents. Barret, JM; Etiévant, C; Hill, BT; Kruczynski, A, 2002) | 0.31 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||